Key result
Early circulating levels of plasma MMP-2 measured before and after primary PCI were significantly correlated with infarct size and left ventricular dysfunction at 5 days and 4 months in STEMI patients.
Why the study?
Do early measurements of plasma MMP-2 predict infarct size and ventricular dysfunction in patients with STEMI undergoing primary PCI?
Cohort (n=58)
Do early measurements of plasma MMP-2 predict infarct size and ventricular dysfunction in patients with STEMI undergoing primary PCI?
Early measurement of plasma MMP-2 before and shortly after primary PCI in STEMI patients predicts subsequent infarct size and left ventricular dysfunction.
Answers are grounded in this paper and cite their sources.
Early MMP-2 levels may aid post-STEMI risk stratification; leaves open clinical utility pending prospective validation.
BACKGROUND: Immediate reopening of the acutely occluded infarct-related artery via primary PCI is the preferred treatment in ST-elevation myocardial infarction (STEMI). However, the sudden reinitiation of blood flow can lead to a local acute inflammatory response with further endothelial and myocardial damage, so-called reperfusion injury. The activation of matrix metalloproteinases (MMPs) is suggested to be a key event in this process. OBJECTIVES: To investigate circulating MMPs, tissue inhibitors of metalloproteinases (TIMPs) and myeloperoxidase (MPO) in relation to infarct size, left ventricular dysfunction and remodelling in a STEMI population undergoing PCI. METHODS: 58 Patients with STEMI undergoing primary PCI were included. Blood samples were collected at baseline before PCI and at 12, 24 and 48 h for later analysis of MMPs, TIMPs and MPO by ELISA. Infarct size, left ventricular (LV) dysfunction and remodelling were assessed by cardiac MRI at 5 days and 4 month after STEMI. RESULTS: Plasma MMP-2 at 0 and 12 h showed a consistent and significant correlation with infarct size and LV dysfunction measured both at 5 days and at 4 months and correlated well with troponin I measurements. For TIMP-1 and TIMP-2 some support was found for associations with infarct size and LV dysfunction, but these were not as consistent as for MMP-2. MMP-8, MMP-9 and MPO did not overall correlate with measures of infarct size, LV dysfunction or remodelling. CONCLUSIONS: In patients with STEMI, circulating levels of MMP-2, measured early and even before reperfusion therapy, are strongly associated with infarct size and LV dysfunction. This provides further evidence for the role of MMP-2 in ischaemia-reperfusion injury.
No takes yet. Share an insight, caveat, or question.
Nilsson et al. (2011) conducted a cohort in ST-elevation myocardial infarction (STEMI) (n=58). Plasma MMP-2 levels was evaluated on Infarct size and left ventricular dysfunction assessed by cardiac MRI. Early circulating levels of plasma MMP-2 measured before and after primary PCI were significantly correlated with infarct size and left ventricular dysfunction at 5 days and 4 months in STEMI patients.
Synapse has enriched 10 related papers. Consider them for comparative context: